The prognosis for diffusely infiltrating gliomas at World Health Organization(WHO)grade 2-4 remains dismal due to their heterogeneity.The rapid development of genome-wide molecular-profiling-associated studies has gre...The prognosis for diffusely infiltrating gliomas at World Health Organization(WHO)grade 2-4 remains dismal due to their heterogeneity.The rapid development of genome-wide molecular-profiling-associated studies has greatly promoted the accuracy of glioma classification.Thus,the latest version of the WHO classification of the central nervous system tumors published in 2021 has incorporated more molecular biomarkers together with histological features for the diagnosis of gliomas.Advanced usage of molecular pathology in clinical diagnostic practice provides also new opportunities for the therapy of patients with glioma,including surgery,radiotherapy and chemotherapy,targeted therapy,immunotherapy,and more precision clinical trials.Herein,we highlight the updates in the classification of gliomas according to the latest WHO guidelines and summarize the clinically relevant molecular markers by focusing on their applications in clinical practice.We also review the advances in molecular features of gliomas,which can facilitate the development of glioma therapies,thereby discussing the challenges and future directions of molecular pathology toward precision medicine for patients with glioma.展开更多
目的检测O6-甲基鸟嘌呤-DNA甲基转移酶(O6-methylguanine-DNA methyltransferase,MGMT)基因启动子区甲基化与维吾尔族子宫颈鳞癌之间的相关性。方法采用甲基化特异性聚合酶链反应(methylation specific PCR,MSP)对41例维吾尔族妇女子宫...目的检测O6-甲基鸟嘌呤-DNA甲基转移酶(O6-methylguanine-DNA methyltransferase,MGMT)基因启动子区甲基化与维吾尔族子宫颈鳞癌之间的相关性。方法采用甲基化特异性聚合酶链反应(methylation specific PCR,MSP)对41例维吾尔族妇女子宫颈鳞癌组织及32名正常维吾尔族妇女子宫颈组织进行甲基化检测。结果32名正常子宫颈组织MGMT基因启动子区均未发生甲基化,为非甲基化状态;41例子宫颈鳞癌组织中共有13例发生MGMT基因启动子区甲基化(32%)。结论MGMT基因启动子区甲基化可能部分参与维吾尔族妇女子宫颈癌的发生发展过程,是维吾尔族子宫颈鳞癌发生过程中常见的分子事件,有可能作为维吾尔族妇女子宫颈癌诊断的肿瘤标志物。展开更多
基金Beijing Nova Program(No.Z201100006820118)National Natural Science Foundation of China(Nos.82192894 and 81903078)Research Unit of Accurate Diagnosis,Treatment,and Translational Medicine of Brain Tumors Chinese(No.2019-I2M-5-021)
文摘The prognosis for diffusely infiltrating gliomas at World Health Organization(WHO)grade 2-4 remains dismal due to their heterogeneity.The rapid development of genome-wide molecular-profiling-associated studies has greatly promoted the accuracy of glioma classification.Thus,the latest version of the WHO classification of the central nervous system tumors published in 2021 has incorporated more molecular biomarkers together with histological features for the diagnosis of gliomas.Advanced usage of molecular pathology in clinical diagnostic practice provides also new opportunities for the therapy of patients with glioma,including surgery,radiotherapy and chemotherapy,targeted therapy,immunotherapy,and more precision clinical trials.Herein,we highlight the updates in the classification of gliomas according to the latest WHO guidelines and summarize the clinically relevant molecular markers by focusing on their applications in clinical practice.We also review the advances in molecular features of gliomas,which can facilitate the development of glioma therapies,thereby discussing the challenges and future directions of molecular pathology toward precision medicine for patients with glioma.
文摘目的检测O6-甲基鸟嘌呤-DNA甲基转移酶(O6-methylguanine-DNA methyltransferase,MGMT)基因启动子区甲基化与维吾尔族子宫颈鳞癌之间的相关性。方法采用甲基化特异性聚合酶链反应(methylation specific PCR,MSP)对41例维吾尔族妇女子宫颈鳞癌组织及32名正常维吾尔族妇女子宫颈组织进行甲基化检测。结果32名正常子宫颈组织MGMT基因启动子区均未发生甲基化,为非甲基化状态;41例子宫颈鳞癌组织中共有13例发生MGMT基因启动子区甲基化(32%)。结论MGMT基因启动子区甲基化可能部分参与维吾尔族妇女子宫颈癌的发生发展过程,是维吾尔族子宫颈鳞癌发生过程中常见的分子事件,有可能作为维吾尔族妇女子宫颈癌诊断的肿瘤标志物。
